Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 15/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31292208 | 0.82 | DDB1 (0.45) | DDB1CRBNBRD4CREBBPGSPT1 | |
| SCHEMBL24938770 | 0.82 | DDB1 (0.44) | DDB1CRBNBRD4CREBBPGSPT1 | |
| SCHEMBL31028610 | 0.81 | DDB1 (0.43) | DDB1CRBNBRD4CREBBPGSPT1 | |
| SCHEMBL24597653 | 0.81 | DDB1 (0.43) | DDB1CRBNBRD4CREBBPGSPT1 | |
| SCHEMBL29750605 | 0.81 | DDB1 (0.43) | DDB1CRBNBRD4CREBBPGSPT1 | |
| SCHEMBL31292414 | 0.80 | CRBN (0.40) | DDB1CRBNGSPT1 | |
| SCHEMBL31292662 | 0.78 | DDB1 (0.48) | DDB1CRBNBRD4CREBBPGSPT1 | |
| SCHEMBL25079169 | 0.78 | CRBN (0.56) | DDB1CRBNBRD4CREBBPGSPT1 | |
| SCHEMBL24939755 | 0.78 | DDB1 (0.45) | DDB1CRBNBRD4CREBBPGSPT1 | |
| SCHEMBL25079223 | 0.77 | CRBN (0.54) | DDB1CRBNGSPT1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | DDB1 2513/4885CRBN 3136/4885BRD4 1945/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | DDB1 2513/4885CRBN 3136/4885BRD4 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.